Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study

A. Ardizzoni, M. R. Sertoli, A. Corcione, M. C. Pennucci, E. Baldini, E. Intra, M. Ferrarini, R. Rosso, P. Mazzanti, V. Pistoia

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Two series of five consecutive patients with small cell lung cancer were treated with an "accelerated" chemotherapy regimen of cyclophosphamide-doxorubicin-vincristine (CAV) and cisplatin-etoposide (PE) alternated possibly every week. In the first group of patients (median age 49 years, range 46-52) recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) was given as soon as grade IV leukopenia occurred, while in the second group (median age 59 years, 55-68) no growth factor was administered. The mean interval between chemotherapy courses and the mean duration of chemotherapy were 10 and 57 days, respectively, in the patients supported with GM-CSF compared with 13 and 72 days in the control group. One GM-CSF treated patient was withdrawn after the third cycle because of severe toxicity. The mean white blood cell and platelet nadirs were 600 and 46 000/μl in the first group vs. 840 and 105 000/sml in the controls. Overall chemotherapy dose-intensity was increased by two fold in the patients given GM-CSF compared with a 1.5 fold increase in the control patients. In all cases, irrespective of their treatment, there was an impaired colony forming capacity of circulating and marrow haemopoietic progenitor cells when grade IV leukopenia occurred, with recovery after the end of leukopenia. This pilot study suggests that accelerated CAV/PE chemotherapy is feasible both with and without GM-CSF. Different GM-CSF schedules as well as combinations of different haemopoietic growth factors may further improve dose-intensity.

Original languageEnglish
Pages (from-to)937-941
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume26
Issue number9
DOIs
Publication statusPublished - 1990

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Non-Small Cell Lung Carcinoma
Drug Therapy
Leukopenia
Vincristine
Doxorubicin
Cyclophosphamide
Intercellular Signaling Peptides and Proteins
Small Cell Lung Carcinoma
Etoposide
Cisplatin
Appointments and Schedules
Leukocytes
Stem Cells
Blood Platelets
Age Groups
Bone Marrow
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Accelerated chemotherapy with or without GM-CSF for small cell lung cancer : a non-randomised pilot study. / Ardizzoni, A.; Sertoli, M. R.; Corcione, A.; Pennucci, M. C.; Baldini, E.; Intra, E.; Ferrarini, M.; Rosso, R.; Mazzanti, P.; Pistoia, V.

In: European Journal of Cancer and Clinical Oncology, Vol. 26, No. 9, 1990, p. 937-941.

Research output: Contribution to journalArticle

Ardizzoni, A. ; Sertoli, M. R. ; Corcione, A. ; Pennucci, M. C. ; Baldini, E. ; Intra, E. ; Ferrarini, M. ; Rosso, R. ; Mazzanti, P. ; Pistoia, V. / Accelerated chemotherapy with or without GM-CSF for small cell lung cancer : a non-randomised pilot study. In: European Journal of Cancer and Clinical Oncology. 1990 ; Vol. 26, No. 9. pp. 937-941.
@article{c81801d85c6747c5b8550bb9b636b85f,
title = "Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study",
abstract = "Two series of five consecutive patients with small cell lung cancer were treated with an {"}accelerated{"} chemotherapy regimen of cyclophosphamide-doxorubicin-vincristine (CAV) and cisplatin-etoposide (PE) alternated possibly every week. In the first group of patients (median age 49 years, range 46-52) recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) was given as soon as grade IV leukopenia occurred, while in the second group (median age 59 years, 55-68) no growth factor was administered. The mean interval between chemotherapy courses and the mean duration of chemotherapy were 10 and 57 days, respectively, in the patients supported with GM-CSF compared with 13 and 72 days in the control group. One GM-CSF treated patient was withdrawn after the third cycle because of severe toxicity. The mean white blood cell and platelet nadirs were 600 and 46 000/μl in the first group vs. 840 and 105 000/sml in the controls. Overall chemotherapy dose-intensity was increased by two fold in the patients given GM-CSF compared with a 1.5 fold increase in the control patients. In all cases, irrespective of their treatment, there was an impaired colony forming capacity of circulating and marrow haemopoietic progenitor cells when grade IV leukopenia occurred, with recovery after the end of leukopenia. This pilot study suggests that accelerated CAV/PE chemotherapy is feasible both with and without GM-CSF. Different GM-CSF schedules as well as combinations of different haemopoietic growth factors may further improve dose-intensity.",
author = "A. Ardizzoni and Sertoli, {M. R.} and A. Corcione and Pennucci, {M. C.} and E. Baldini and E. Intra and M. Ferrarini and R. Rosso and P. Mazzanti and V. Pistoia",
year = "1990",
doi = "10.1016/0277-5379(90)90614-Y",
language = "English",
volume = "26",
pages = "937--941",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - Accelerated chemotherapy with or without GM-CSF for small cell lung cancer

T2 - a non-randomised pilot study

AU - Ardizzoni, A.

AU - Sertoli, M. R.

AU - Corcione, A.

AU - Pennucci, M. C.

AU - Baldini, E.

AU - Intra, E.

AU - Ferrarini, M.

AU - Rosso, R.

AU - Mazzanti, P.

AU - Pistoia, V.

PY - 1990

Y1 - 1990

N2 - Two series of five consecutive patients with small cell lung cancer were treated with an "accelerated" chemotherapy regimen of cyclophosphamide-doxorubicin-vincristine (CAV) and cisplatin-etoposide (PE) alternated possibly every week. In the first group of patients (median age 49 years, range 46-52) recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) was given as soon as grade IV leukopenia occurred, while in the second group (median age 59 years, 55-68) no growth factor was administered. The mean interval between chemotherapy courses and the mean duration of chemotherapy were 10 and 57 days, respectively, in the patients supported with GM-CSF compared with 13 and 72 days in the control group. One GM-CSF treated patient was withdrawn after the third cycle because of severe toxicity. The mean white blood cell and platelet nadirs were 600 and 46 000/μl in the first group vs. 840 and 105 000/sml in the controls. Overall chemotherapy dose-intensity was increased by two fold in the patients given GM-CSF compared with a 1.5 fold increase in the control patients. In all cases, irrespective of their treatment, there was an impaired colony forming capacity of circulating and marrow haemopoietic progenitor cells when grade IV leukopenia occurred, with recovery after the end of leukopenia. This pilot study suggests that accelerated CAV/PE chemotherapy is feasible both with and without GM-CSF. Different GM-CSF schedules as well as combinations of different haemopoietic growth factors may further improve dose-intensity.

AB - Two series of five consecutive patients with small cell lung cancer were treated with an "accelerated" chemotherapy regimen of cyclophosphamide-doxorubicin-vincristine (CAV) and cisplatin-etoposide (PE) alternated possibly every week. In the first group of patients (median age 49 years, range 46-52) recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) was given as soon as grade IV leukopenia occurred, while in the second group (median age 59 years, 55-68) no growth factor was administered. The mean interval between chemotherapy courses and the mean duration of chemotherapy were 10 and 57 days, respectively, in the patients supported with GM-CSF compared with 13 and 72 days in the control group. One GM-CSF treated patient was withdrawn after the third cycle because of severe toxicity. The mean white blood cell and platelet nadirs were 600 and 46 000/μl in the first group vs. 840 and 105 000/sml in the controls. Overall chemotherapy dose-intensity was increased by two fold in the patients given GM-CSF compared with a 1.5 fold increase in the control patients. In all cases, irrespective of their treatment, there was an impaired colony forming capacity of circulating and marrow haemopoietic progenitor cells when grade IV leukopenia occurred, with recovery after the end of leukopenia. This pilot study suggests that accelerated CAV/PE chemotherapy is feasible both with and without GM-CSF. Different GM-CSF schedules as well as combinations of different haemopoietic growth factors may further improve dose-intensity.

UR - http://www.scopus.com/inward/record.url?scp=0025696179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025696179&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(90)90614-Y

DO - 10.1016/0277-5379(90)90614-Y

M3 - Article

C2 - 2177614

AN - SCOPUS:0025696179

VL - 26

SP - 937

EP - 941

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -